Literature DB >> 15083919

Effects of different dialysis modalities on cardiac autonomic dysfunctions in end-stage renal disease patients: one year prospective study.

Belda Dursun1, Fatih Demircioglu, Halil Ibrahim Varan, Ibrahim Basarici, Mehmet Kabukcu, Fevzi Ersoy, Filiz Ersel, Gultekin Suleymanlar.   

Abstract

Cardiac autonomic dysfunction (CAD) is a common problem in patients with end-stage renal disease (ESRD) and may contribute to the risk of cardiac mortality. Long-term effects of dialysis modalities on CAD in ESRD patients are not clear. In this one-year prospective study, we studied the effects of different dialysis modalities on CAD in ESRD patients. The study consisted of 20 ESRD patients who had the indications for initiating dialysis therapy (13 hemodialysis and 7 CAPD patients) and 15 healthy controls (M/F: 5/10; age 30 +/- 4). In all the subjects, first at the beginning of study (in patient groups just before initiating dialysis therapy) and then after 12 months, we studied 24 hours ECG-Holter monitoring and heart rate variability parameters (time and frequency domain analysis parameters; SDNN: standard deviations of nn intervals, rMSSD: square root of the median of standard deviation, HRVI: heart rate variability index, LF/HF: low frequency/high frequency). In ESRD patients, before dialysis therapy, all the parameters of time domain analysis were significantly lower compared to control group (p = 0.001). In patient groups, after dialysis therapy (on the 12th month), significant improvement was observed in time domain analysis parameters (p = 0.001). When dialysis modalities were compared, the increase in the time domain analysis parameters was significantly greater in the CAPD group compared to hemodialysis (HD) group. Our findings suggest that CAD is frequent in ESRD patients, a dialysis therapy of 12 months can cause significant improvement on CAD and the ameliorative effect of CAPD is better than HD.

Entities:  

Mesh:

Year:  2004        PMID: 15083919     DOI: 10.1081/jdi-120028541

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  8 in total

Review 1.  Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review.

Authors:  Ibrahim M Salman
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

Review 2.  Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults.

Authors:  L Vale; J Cody; S Wallace; C Daly; M Campbell; A Grant; I Khan; C Donaldson; A Macleod
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 3.  Prognostic significance and therapeutic option of heart rate variability in chronic kidney disease.

Authors:  Jing Zhang; Ningning Wang
Journal:  Int Urol Nephrol       Date:  2013-03-29       Impact factor: 2.370

Review 4.  The management of diabetic neuropathy in CKD.

Authors:  Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman
Journal:  Am J Kidney Dis       Date:  2009-12-30       Impact factor: 8.860

5.  Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study.

Authors:  Rulan S Parekh; Lucy A Meoni; Bernard G Jaar; Stephen M Sozio; Tariq Shafi; Gordon F Tomaselli; Joao A Lima; Larisa G Tereshchenko; Michelle M Estrella; W H Linda Kao
Journal:  BMC Nephrol       Date:  2015-04-24       Impact factor: 2.388

6.  The effect of on-line hemodiafiltration on heart rate variability in end-stage renal disease.

Authors:  Kyung Won Park; Sang Kyun Bae; Buhyun Lee; Jeong Hun Baek; Jin Woo Park; Sung Jin Moon; Soo Young Yoon
Journal:  Kidney Res Clin Pract       Date:  2013-07-10

7.  Influence of chronic renal failure on the heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT.

Authors:  Andrea De Lorenzo; Ronaldo S L Lima
Journal:  J Nucl Cardiol       Date:  2008-03-06       Impact factor: 3.872

8.  Improved cardiovascular autonomic function and decreased protein-bound uremic toxins in patients with end-stage renal disease after peritoneal dialysis.

Authors:  Ben-Chung Cheng; Yun-Ru Lai; Chih-Cheng Huang; Cheng-Hsien Lu
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.